Skye Bioscience appoints Dr. Keith Ward to board, promotes Tu Diep to CDO

Skye Bioscience, Inc.

Dr. Ward elected to board; receives $40K annual director fee, $1K committee pay, and options for 250K shares vesting monthly over one year.
CEO Punit Dhillon granted 2,000,000 RSUs and 3,090,000 stock options at $0.058/share; Kaitlyn Arsenault granted 1,000,000 RSUs and 1,770,000 options.
Tu Diep promoted from SVP of Development to Chief Development Officer, effective immediately.
Options to Dhillon and Arsenault vest 25% at one year then monthly; fully vest on change of control; expire Dec 14, 2031.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Keith Ward

Director

SKYE · Skye Bioscience, Inc.

Effective: 2021-12-14
Filed: December 20, 2021, 6:59 PM ET

elected Dr. Keith Ward, Ph.D. to fill such vacancy and serve as a director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Ward was elected as Director at Skye Bioscience, Inc..

Action: elected
Role: Director

Exact text from the filing

elected Dr. Keith Ward, Ph.D. to fill such vacancy and serve as a director

View on SEC.gov

Skye Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001516551-21-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.